Psychiatry Research
Volume 129, Issue 2 , Pages 159-169 , 15 December 2004

A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition

  • Ashok Malla

      Affiliations

    • Division of Clinical Research, Department of Psychiatry, McGill University, Douglas Hospital Research Centre, 6875 LaSalle Boulevard, Verdun, Quebec, Canada 4H4 1R3
    • Corresponding Author InformationCorresponding author. Tel.: +1 514 761 6131x3390; fax: +1 514 888 4064.
    • ,
  • Ross Norman

      Affiliations

    • University of Western Ontario and London Health Sciences Centre, London, Ontario, Canada
    • ,
  • Derek Scholten

      Affiliations

    • University of Western Ontario and London Health Sciences Centre, London, Ontario, Canada
    • ,
  • Laurel Townsend

      Affiliations

    • University of Western Ontario and London Health Sciences Centre, London, Ontario, Canada
    • ,
  • Rahul Manchanda

      Affiliations

    • University of Western Ontario and London Health Sciences Centre, London, Ontario, Canada
    • ,
  • Jatinder Takhar

      Affiliations

    • University of Western Ontario and London Health Sciences Centre, London, Ontario, Canada
    • ,
  • Raj Haricharan

      Affiliations

    • University of Western Ontario and London Health Sciences Centre, London, Ontario, Canada

Received 12 December 2003 ,Revised 23 July 2004 ,Accepted 31 July 2004.

References 

  1. Andreasen NC. Scale for the Assessment of Negative Symptoms (Manual). Iowa City: University of Iowa Press; 1983;
  2. Andreasen NC. Scale for the Assessment of Positive Symptoms (Manual). Iowa City: University of Iowa Press; 1984;
  3. Arvanitis LA, Miller BF. Seroquel Trial 13 Study Group: multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biological Psychiatry. 1997;42:233–246
  4. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin. 1982;8:470–484
  5. Chouinard G, Ross-Chouinard G. Extrapyramidal symptom rating scale. Canadian Journal of Neurological Sciences. 1980;7:223
  6. Conley RR, Mahmoud R. A randomized double blind study of risperidone and olanzapine in the treatment of schizophrenia or schizo-affective disorder. American Journal of Psychiatry. 2001;158:765–774
  7. Cornblatt BA, Keilp JG. Impaired attention, genetics and psychopathology of schizophrenia. Schizophrenia Bulletin. 1994;20:96–104
  8. Emsley R, Oosthuizen P. The new and evolving pharmacotherapy of schizophrenia. Psychiatric Clinics of North America. 2003;26:141–163
  9. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM IV Axis 1 Disorders (SCID-1) Clinical Version. New York: Biometrics Research Department, New York State Psychiatric Institute; 1995;
  10. Golden JC. Stroop Color and Word Test. Chicago, IL: Stoeling; 1978;
  11. Gronwall DMA. Paced auditory serial addition task: a measure of recovery from concussion. Perceptual and Motor Skills. 1977;44:367–373
  12. Gupta S, Andreasen NC, Arndt S, Flaum M, Schultz SK, Hubbard WC, et al. Neurological soft signs in neuroleptic-naïve and neuroleptic-treated schizophrenic patients and in normal comparison subjects. American Journal of Psychiatry. 1995;152:191–196
  13. Gureje O, Miles W, Grainger D, Lambert T, McGrath J, Tran P, et al. Olanzapine vs. risperidone in the management of schizophrenia: a randomized double blind trial in Australia and New Zealand. Schizophrenia Research. 2003;61:303–314
  14. Häfner H, Riecher-Rossler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A, et al. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophrenia Research. 1992;6:209–223
  15. Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry. 2001;15:176–184
  16. Heaton RK. Wisconsin Card Sorting Test Manual. Odessa, FL: Psychological Assessment Resources; 1981;
  17. Ho B, Miller D, Nopoulos P, Andreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. Journal of Clinical Psychiatry. 1999;60:658–663
  18. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry. 1988;45:789–796
  19. Keefe SEK, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bulletin. 1999;25:202–222
  20. Keshavan MS, Sanders RD, Sweeney JA, Diwadkar VA, Goldstein G, Pettegrew JW, et al. Diagnostic specificity and neuroanatomical validity of neurological abnormalities in first episode psychoses. American Journal of Psychiatry. 2003;160:1298–1304
  21. Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. Journal of Clinical Psychopharmacology. 1997;17:308–313
  22. Kraepelin, E., 1918. Dementia Praecox and Paraphrenia. Translated by R.M. Barclay. R.E. Krieger, New York.
  23. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophrenia Research. 1999;35:51–68
  24. Liddle PF. The symptoms of chronic schizophrenia: a re-examination of the positive-negative dichotomy. British Journal of Psychiatry. 1987;151:145–151
  25. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry. 2003;160:1396–1404
  26. Malla AK, Norman RMG, Williamson P, Cortese L, Diaz F. Three syndrome concept of schizophrenia: a factor analytic study. Schizophrenia Research. 1993;10:143–150
  27. Malla A, Norman R, Manchanda R, Ahmed R, Scholten D, Harricharan R, et al. One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophrenia Research. 2002;54:231–242
  28. Malla AK, Norman R, Manchanda R, McLean T, Harricharan R, Cortese L, et al. Status of patients with first-episode psychosis after one year of phase-specific community oriented treatment. Psychiatric Services. 2002;53:458–463
  29. Malla AK, Norman RMG, McLean TS, Scholten D, Townsend L. A Canadian programme for early intervention in non-affective psychotic disorders. Australian and New Zealand Journal of Psychiatry. 2003;37:407–413
  30. Marder SR, Meilbach RC. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry. 1994;151:825–835
  31. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin. 1999;25:233–255
  32. Nelson HE. National Adult Reading Test (NART): Test Manual. Windsor, UK: NFER Nelson; 1982;
  33. Owens DGC, Johnstone EC, Frith CD. Spontaneous involuntary disorders of movement: their prevalence, severity and distribution in chronic schizophrenics with and without treatment with neuroleptics. Archives of General Psychiatry. 1982;39:452–461
  34. Purdon SC. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophrenia Research. 1999;35:51–60
  35. Purdon SE, Jones BDW, Stip E, Labelle A, Addington D, David SR, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Archives of General Psychiatry. 2000;57:249–258
  36. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery. Tuscon, AZ: Neuropsychology Press; 1985;
  37. Rummel C, Hamann J, Kissling W, Leucht S. New generation antipsychotics for first episode schizophrenia. In: Cochrane Database Systematic Reviews [internet]. Oxford: Update Software, 2001. 2003;Cited 2003 Sept. 12
  38. Russell AJ, Munro J, Jones PB, Hayward P, Hemsley DR, Murray RM. The National Adult Reading Test as a measure of premorbid IQ in schizophrenia. British Journal of Clinical Psychology. 2000;39:297–305
  39. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. 1970;212:11–19
  40. Task Force of the World Psychiatric Association . The usefulness of the second-generation antipsychotic medications. Current Opinion in Psychiatry. 2002;15:S7–S16
  41. Thurstone LL, Thurstone TG. Primary Mental Abilities. Chicago: Science Research Associates; 1962;
  42. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry. 1997;154:457–465
  43. Townsend LA, Malla AK, Norman RM. Cognitive functioning in stabilized first episode psychosis patients. Psychiatry Research. 2001;104:119–131
  44. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. British Journal of Psychiatry. 1998;172:499–505
  45. Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed.. New York: Psychological; 1997;
  46. Wechsler D. Wechsler Memory Scale. 3rd ed.. New York: Psychological Corporation; 1997;
  47. Weiser M, Shneider-Beeri M, Nakash N, Brill N, Bawnik O, Reiss S, et al. Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS?. Schizophrenia Research. 2000;46:81–89
  48. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry. 1997;154:782–791

PII: S0165-1781(04)00207-0

doi: 10.1016/j.psychres.2004.07.008

Psychiatry Research
Volume 129, Issue 2 , Pages 159-169 , 15 December 2004

Article Tools